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Abstract
Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003,
result in high morbidity and mortality. It is feared that these viruses become pandemic, therefore the development of safe
and effective vaccines is desirable. MVA-based H5N1 vaccines already proved to be effective when two immunizations with
high doses were used. Dose-sparing strategies would increase the number of people that can be vaccinated when the
amount of vaccine preparations that can be produced is limited. Furthermore, protective immunity is induced ideally after a
single immunization. Therefore the minimal requirements for induction of protective immunity with a MVA-based H5N1
vaccine were assessed in mice. To this end, mice were vaccinated once or twice with descending doses of a recombinant
MVA expressing the HA gene of influenza virus A/Vietnam/1194/04. The protective efficacy was determined after challenge
infection with the homologous clade 1 virus and a heterologous virus derived from clade 2.1, A/Indonesia/5/05 by assessing
weight loss, virus replication and histopathological changes. It was concluded that MVA-based vaccines allowed significant
dose-sparing and afford cross-clade protection, also after a single immunization, which are favorable properties for an H5N1
vaccine candidate.
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Introduction
Over 400 human cases of infections with highly pathogenic
avian influenza (HPAI) viruses of the H5N1 subtype have been
reported since 2003. More than 60% of these cases had a fatal
outcome and new cases continue to be reported frequently[1].
Once these viruses become transmittable from human-to-human
by adaption to their new host, a new influenza pandemic is
imminent. Neutralizing antibodies against H5N1 viruses are
virtually absent in the human population and already nine
different clades of antigenically distinct viruses have been
identified [2]. Therefore, the development of safe and effective
vaccines that, ideally, induce cross-clade immunity has high
priority [2–4]. The implementation of reverse genetics for the
generation of vaccine strains and cell culture technology
contribute to the rapid availability of pandemic influenza vaccines
[5–14]. In addition, the use of adjuvants can increase the
immunogenicity of seasonal and pandemic influenza vaccines
and may lower the amount of antigen needed for the induction of
protective antibody responses [15–19].
The development of alternative novel generations of influenza
vaccines may mitigate the envisaged shortage of vaccine doses in
the future. For example, vector vaccines based on recombinant
adenovirus or poxvirus expressing selected influenza virus genes
have been shown to be immunogenic and to afford protection
against infection with H5N1 virus in animal models [20–26].
Especially the replication-deficient modified vaccinia virus
Ankara (MVA), constitutes an attractive vaccine production
platform. This virus was originally developed as a vaccine against
smallpox and has been administered to .120.000 humans without
significant side effects [27]. In addition, administration of MVA to
immunocompromised individuals is safe and does not lead to
systemic disease often associated with the application of replicating
vaccinia virus [28,29]. Its potential as vaccine candidate has been
demonstrated for a number of infectious pathogens [30–33].
Recently, we have demonstrated that immunization with a
recombinant MVA expressing the HA gene of influenza H5N1
virus A/Vietnam/1194/04 (MVA-HA-VN/04) induced protec-
tive immunity against infection with the homologous and a
heterologous antigenically distinct virus in mice and macaques
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[24,25]. In these studies animals were immunized twice with
relative high doses (.108 pfu) of recombinant MVA. However, to
stretch the number of individuals that can be vaccinated with any
given amount of vaccine preparation that can be produced it
would be desirable if dose-sparing can be achieved. Furthermore,
when a pandemic is imminent, there might not be enough time to
induce protective immunity with a two-dose immunization
regimen. Thus, ideally, protective immunity is induced after
immunization with lower doses and preferable after a single
immunization, which are key elements in the development of
pandemic influenza vaccines. In the present study, we determined
the minimal requirements for the induction of protective immunity
with MVA-HA-VN/04 against the homologous virus and against
an antigenically distinct H5N1 strain.
Two immunizations with MVA-HA-VN/04 at doses 10,000-
fold lower than used previously [25] significantly reduced weight
loss and mortality caused by challenge infection with influenza
viruses A/Vietnam/1194/04 (clade 1) and A/Indonesia/5/05
(clade 2.1). Strikingly, also protection against the development of
clinical signs and mortality was achieved with a single immuni-
zation with 105 pfu of MVA-HA-VN/04. The clinical protection
correlated with a reduction of virus replication and lung
pathology.
Thus, apart from the favorable properties already attributed to
recombinant MVA [33], the possibilities of dose sparing and single
shot immunization regimens make this vector even more attractive
as a pandemic influenza vaccine candidate.
Results
Antibody Responses Induced by Immunization with
MVA-HA-VN/04
After a single immunization with MVA-HA-VN/04, only mice
that received a dose of 106 or 108 pfu developed detectable
antibody titers (Table 1). Four weeks after immunization these
animals had HI geometric mean titers (GMT) of 6.8 (SD=1.8)
and 15.7 (SD=2.6) against the homologous virus (A/VN/1194/
04) and 5.5 (SD=1.4) and 6.1 (SD=1.8) against the heterologous
virus (A/IND/5/05), respectively. As shown in table 1, also virus-
neutralizing antibodies were detected after a single immunization
with 106 or 108 pfu with GMT 5.4 (SD=1.4) and 5.7 (SD=1.5)
against the homologous strain respectively. Only mice immunized
with 108 pfu of MVA-HA-VN/04 developed virus neutralizing
antibody titers against the heterologous strain. Mice that received
two immunizations with 103, 104, 105 or 106 pfu of MVA-HA-
VN/04 developed HI GMT of 6.3 (SD=2.1), 16.2 (SD=3.8),
77.1 (SD=4.2) and 71.9 (3.3) respectively against the homologous
strain. Those that received 105 and 106 pfu also developed
detectable HI antibodies against the influenza virus A/IND/5/05
with GMT 7.7 (SD=2.6) and 7.7 (SD=2.3). In the VN assay,
antibodies against the homologous strain were detected with GMT
of 5.5 (SD=1.6), 18.0 (SD=4.4) and 15.2 (SD=3.9) in mice
immunized with 104, 105 or 106 pfu of MVA-HA-VN/04,
respectively. The mice that were immunized twice with 105 and
106 pfu developed virus-neutralizing antibodies against the
heterologous strain with GMT of 7.5 (SD=2.9) and 6.2
(SD=2.0).
Protection against Clinical Signs after Infection with
Influenza A/H5N1 Virus
From two to three days p.i. onwards, unprotected control
animals started to develop clinical signs, irrespective of the
challenge virus that was used, although infection with influenza
A/IND/5/05 caused more severe disease.
Mice that received PBS or wtMVA once or twice displayed
reduced muscle strength, and around day 4 p.i. hunched back
posture and heavy breathing. A similar clinical presentation was
observed in mice that received one or two immunizations with 103
pfu MVA-HA-VN/04 and that were subsequently infected with
influenza virus A/IND/5/05. These mice eventually succumbed
from infection or had to be taken out of the experiment because
they reached humane endpoints.
Mice that received a single immunization with 104 or 105 pfu
MVA-HA-VN/04, and those vaccinated twice with 103 pfu,
developed mild clinical signs after infection with the homologous
influenza virus A/VN/1194/04. Also mice vaccinated twice with
104 pfu but infected with the heterologous strain A/IND/5/05
had a mild clinical outcome of infection and recovered from
infection.
Mice vaccinated once with 106 or 108 pfu and those vaccinated
twice with 105 or 106 pfu did not show any clinical signs after
infection regardless the virus that was used for infection.
In general, the severity of the clinical signs correlated with the
extent of weight loss. Mice vaccinated once with doses .105 pfu
did not loose weight after infection with influenza virus A/VN/04
and fully recovered (Figure 1). After challenge infection with A/
IND/5/05 some weight loss was observed, but it was limited
considerably compared to control mice or those vaccinated with
doses of,105 pfu MVA-HA-VN/04. Two vaccinations with doses
as low as 104 pfu of MVA-HA-VN/04 fully protected mice from
weight loss after infection with the homologous strain. Even two
vaccinations with 103 pfu prevented severe weight loss observed in
PBS control mice and those vaccinated with 108 pfu of the empty
vector. Two vaccinations with doses .104 pfu also protected mice
from severe weight loss after infection with influenza virus A/
IND/5/05
Survival after Infection with Influenza A/H5N1 Virus
Mice that developed severe clinical signs after H5N1 infection
and that showed weight loss of more than 20% were euthanized
for ethical reasons. Mice that received a single shot of PBS,
wtMVA or the lowest dose of MVA-HA-VN/04 (103 pfu) did not
survive past day 7 p.i. with influenza virus A/VN/1194/04 and
A/IND/5/05, and most of them reached humane endpoints six
Table 1. Induction of antibodies to A/VN/1194/04 and
A/IND/5/05 after immunization with MVA-HA-VN/04.
Number of
vaccinations
Dose
MVA-HA-VN/04(1) Assay A/VN/1194/04 A/IND/5/05
One 106 HI 6.8 (1.8)(1) 5.5 (1.4)
108 15.7 (2.6) 6.1 (1.8)
106 VN 5.4 (1.4) -
108 5.7 (1.5) 5.4 (1.4)
Two 103 HI 6.3 (2.1) -
104 16.2 (3.8) -
105 77.1 (4.2) 7.7 (2.6)
106 71.9 (3.3) 7.7 (2.3)
103 VN - -
104 5.5 (1.6) -
105 18.0 (4.4) 7.5 (2.9)
106 15.2 (3.9) 6.2 (2.0)
(1)titers are expressed as GMT (Standard deviation).
doi:10.1371/journal.pone.0007790.t001
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days p.i. (Table 2). Mice immunized once with 104 pfu MVA-HA-
VN/04 had a survival rate of 25% after infection with both the
homologous and heterologous virus. A single vaccination with 105
pfu MVA-HA-VN/04 resulted in 100% survival after infection
with the homologous virus and 50% after infection with influenza
virus A/IND/5/05. A single vaccination with a dose of .106 pfu
MVA-HA-VN/04 prevented mortality caused by infection with
both viruses.
Two immunizations with 103 pfu MVA-HA-VN/04 protected
67% of mice from death caused by infection with A/VN/04, but
not that caused by infection with the heterologous strain A/IND/
5/05 (Table 2). Two immunizations with a dose .104 pfu of
MVA-HA-VN/04, protected mice completely against mortality
caused by infection with both influenza viruses.
MVA-HA-VN/04 Vaccination Reduces Virus Replication in
the Lungs
After one vaccination. Lungs were tested for the presence of
infectious virus on day 4 post infection (p.i.). After infection with
influenza virus A/VN/1194/04 of mice vaccinated with PBS or
wtMVA, the mean virus titers were 108.3 (SD=100.2) and 107.9
(SD=100.5), respectively (Figure 2A). These titers were
significantly higher than that of mice that were vaccinated with
MVA-HA-VN/04 at a dose of 104, 105, 106 or 108 pfu (p,0.05).
The mean virus titer in mice immunized once with 103 pfu of
MVA-HA-VN/04 was 107.5 (SD=100.2), which was still
significantly lower than that of mice that received PBS (p,0.05).
Four days post infection with influenza virus A/IND/5/05 the
mean virus titers in the PBS vaccinated and wtMVA vaccinated
mice were 108.5 (SD=100.6) and 108.7 (SD=100.1) respectively
(Figure 2B). Mice vaccinated with a dose of 103 pfu MVA-HA-VN/
04 had similar mean virus titer of 108.5 (SD=100.8). Vaccination
with higher doses of MVA-HA-VN/04 resulted in lower lung virus
titers. The extent of virus replication was vaccine dose dependent.
The mean A/IND/5/05 virus titers for mice vaccinated with 104,
105, 106 or 108 pfu were 107.6 (SD=100.6), 106.7 (SD=101.4), 107.1
(SD=100.6) and 103.7 (SD=102.8), respectively.
Figure 1. MVA-HA-VN/04 vaccination prevents loss of body weight caused by infection. The bodyweight after infection with influenza
virus A/Vietnam/1194/04 (A, C) and influenza virus A/Indonesia/5/05 (B, D) is shown relative to the body weight before infection(100%). Animals were
infected four weeks after a single immunization (A, B) with: PBS, wtMVA, 103, 104, 105, 106 or 108 pfu of MVA-HA-VN/04. A second group of animals
was infected four weeks after two immunizations (C, D) with PBS, wtMVA, 103, 104, 105 or 106 pfu of MVA-HA-VN/04. (*Indicates weight loss of the
proportion of animals in this group that survived post day 6 infection).
doi:10.1371/journal.pone.0007790.g001
Table 2. Survival after infection with A/VN/1194/04 or
A/IND/5/05.
Number of
vaccinations
Vaccine
preparation Dose(1) A/VN/1194/04 A/IND/5/05
One PBS Mock 0/4 0/4
wtMVA 108 0/4 0/4
MVA-HA-VN/04 103 0/4 0/4
104 1/4 1/4
105 4/4 2/4
106 4/4 4/4
108 4/4 4/4
Two PBS Mock 0/4 0/4
wtMVA 108 0/4 0/4
MVA-HA-VN/04 103 2/3(2) 0/4
104 4/4 4/4
105 4/4 4/4
106 4/4 4/4
(1)Dose of MVA-HA-VN/04 in pfu (immunization in a total volume of 100 ml).
(2)One animal had to be euthanized before infection due to a complication
unrelated to the experiment.
doi:10.1371/journal.pone.0007790.t002
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After two vaccinations. As shown in figure 2C, two
immunizations with MVA-HA-VN/04 resulted in significant
lower lung virus titers four days after infection with the
homologous virus A/VN/1194/04 compared to the PBS or
empty vector inoculated mice, regardless the vaccine dose that was
used. In mice vaccinated with vaccine doses .105, infectious virus
was not detected.
Four days p.i. with influenza virus A/IND/5/05 infectious virus
could not be detected in the lungs of mice that were vaccinated
twice with 105 pfu of MVA-HA-VN/04. In mice vaccinated twice
with 106 pfu the mean virus titer in the lungs was 103.6
(SD=101.7), which was significantly lower than that in the PBS
and wtMVA immunized control mice which had mean titers of
108.5 (SD=100.3) and 108.8 (SD=100.6) respectively (Figure 2D).
Also vaccination with a dose of 104 pfu of MVA-HA-VN/04
significantly reduced the virus titers of A/IND/5/05 compared to
PBS control mice.
Vaccination Prevents Histopathological Changes in the
Lungs after Influenza A/H5N1 Infection
Upon infection with influenza viruses A/VN/1194/04 and A/
IND/5/05, unprotected control mice inoculated with PBS or
empty vector developed a moderate to severe broncho-interstitial
pneumonia within four days (Figure 3). Histopathological changes
were located in multifocal to coalescing lesions with more than
50% of the lungs affected. The lesions were characterized by
marked inflammatory peribronchiolar lymphocytic infiltrates and
occasionally proteinaceous fluid. There was necrosis in the
bronchiolar epithelium resulting in cellular debri in the lumen.
All these histopathological changes were located in multifocal to
coalescing lesions with more than 50% of the lung affected.
Similar lesions were observed in mice vaccinated with 103 pfu of
MVA-HA-VN/04. Mice that were immunized once with 104, 105
or 106 pfu of MVA-HA-VN/04, or twice with 104 pfu were
partially protected against homologous and heterologous challenge
infection. They displayed moderate changes in the lung: moderate
peribronchiolar lymphocytic infiltrate and mild necrosis in the
bronchiolar walls (Figure 3). Fourteen days p.i. normal architec-
ture of the lung was restored in animals from these groups, apart
from some residual peribronchiolar lymphocytic infiltrate and
mild hyperplasia and hypertrophy of the bronchiolar and alveolar
epithelium, consistent with regeneration. Mice vaccinated once
with 108 pfu of MVA-HA-VN/04 or twice with .105 pfu
displayed virtually no histopathological changes in the lung four
days p.i. (Figure 3) or at later time points p.i. with influenza viruses
A/VN/1194/04 or A/IND/5/05.
Detection of Virus-Infected Cells by Immuno-
Histochemistry
The presence of influenza virus-infected cells in the lungs was
detected using a monoclonal antibody against the viral nucleo-
protein, resulting in a red-brown precipitate in the nucleus and less
in the cytoplasm. Four days p.i. with influenza virus A/VN/1194/
04 infected cells were abundantly present in the lungs of control
mice that received PBS or empty vector once or twice or mice
vaccinated with 103 pfu of MVA-HA-VN/04. Also after infection
with influenza virus A/IND/5/05, virus-infected cells were
abundantly present in the lungs of the control mice. A single
vaccination with 103, 104, 105 or 106 pfu of MVA-HA-VN/04 did
not prevent replication of influenza virus A/IND/5/05. The
antigen-expressing cells were epithelial cells in the alveolar wall
(type I and type II like pneumocytes) and bronchiolar epithelial
cells in most of the bronchiolar walls (Figure 3). Mice vaccinated
with 104, 105 or 106 pfu of MVA-HA-VN/04 once or twice with
103 pfu were partially protected against the homologous virus and
had virus-infected cells, predominantly type II like pneumocytes,
Figure 2. MVA-HA-VN/04 vaccination reduces virus replication in the lung. The data represent lung virus titers on day 4 post infection with
influenza virus A/Vietnam/1194/04 and A/Indonesia/5/05 in mice that received one (A, B) or two (C, D) immunization(s) of: PBS, wtMVA or 103, 104,
105, 106 or 108 (single shot only) pfu of MVA-HA-VN/04 as indicated. (* indicates a statistical significant difference with the PBS immunized group
(p,0.05) (** indicates a significant difference with both the PBS and wtMVA immunized group (p,0.05)(*** indicates a statistical significant
difference with the wtMVA immunized group).
doi:10.1371/journal.pone.0007790.g002
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at multiple foci in their lungs (Figure 3). A few single infected cells
were detected in the lungs of animals that had received a single
immunization with 108 pfu MVA-HA-VN/04 and virus-infected
cells were virtually absent in animals that had received two
immunizations with .105 pfu of MVA-HA-VN/04 (Figure 3). No
virus was detectable in any of the animals fourteen days after
infection.
Discussion
In the present study, the minimal requirements were assessed
for the induction of protective immunity in mice against
antigenically distinct influenza A/H5N1 viruses with a recombi-
nant MVA expressing the HA gene of a clade 1 influenza A/
H5N1virus. Two immunizations with a dose as low as 104 pfu of
MVA-HA-VN/04 were sufficient for the induction of protective
immunity not only against the homologous strain but also against
the antigenically distinct strain A/IND/5/05 from clade 2.1.
A dose of 104 pfu is 10.000 fold lower than the dose of 108 pfu
that was used in previous studies that demonstrated the protective
potential of MVA-HA-VN/04 vaccine candidate in mice and
macaques [24,25]. Thus, substantial less vaccine preparation is
needed for the induction of protective immunity in mice. The
possibility of dose-sparing would increase the number of
individuals that can be vaccinated, with any amount of vaccine
preparation, considerably. It was indicated on the website of a
manufacturer of MVA based vaccines (www.bavarian-nordic.com)
that the production capacity would range in tens of millions of
doses, assuming a dose of 108 pfu. If it can be confirmed that also
in humans a dose of 104 pfu is still effective, enough vaccine doses
Figure 3. MVA-HA-VN/04 vaccination reduces histopathological changes induced by infection. Histopathological changes and the
detection of virus-infected cells by immunohistochemistry in the lungs 4 days after infection with influenza A/H5N1 viruses A/VN/1194/04 and A/IND/
5/05. Representative pictures were selected for the different classifications. Magnification: overview (106), bronchiole (206), alveoli (406).
doi:10.1371/journal.pone.0007790.g003
Minimal Dose MVA H5N1 Vaccine
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7790
can be made for a global vaccination campaign. Thus the problem
of the envisaged shortage of pandemic influenza vaccines could be
addressed with the use of the recombinant MVA technology.
Another important issue that complicates the development of
effective H5N1 vaccines is the co-circulation of antigenically
distinct viruses. At present, nine different clades and subclades of
A/H5N1 viruses have been identified and ideally vaccines will
induce protective immunity against viruses of multiple clades. Two
immunizations with MVA-HA-VN/04 afforded cross-clade pro-
tection. It should be noted that also protective effects were
observed with low doses MVA-HA-VN/04 in the absence of
detectable antibody responses specific for the two viruses used for
challenge infection. It is possible that when low doses of vaccine
are used antibody responses are induced below the detection limit,
but which still afford some level of protection. Alternatively, it is
possible that vaccination with low doses MVA-HA-VN/04 primed
for secondary antibody responses or induced HA-specific T cell
responses, which could have contributed to the protective effect.
With higher doses of MVA-HA-VN/04 detectable antibodies were
induced which indicated that the magnitude of the antibody
responses is dependent on the vaccine dose.
In our mouse model, vaccination with two doses of $104 pfu of
MVA-HA-VN/04 reduced virus replication upon challenge
infection significantly, which correlated with a reduction of
histopathological changes in the lung and a reduction in the
presentation of clinical signs, such as weight loss. Only with a high
dose of MVA-HA-VN/04 ($105 pfu) sterilizing immunity was
induced against the homologous strain. In some mice vaccinated
twice with 106 pfu of MVA-HA-VN/04, residual replication of
influenza virus A/IND/5/05 was observed. However, this did not
result in significant differences in clinical endpoints with the group
of mice vaccinated with 105 pfu, in which virus replication was not
detected.
When a pandemic is imminent the rapid induction of protective
immunity by vaccination is desirable and may prevent morbidity
and mortality in selected population groups like health care
workers or those at high risk for complications associated with
infection with influenza viruses. Under these circumstances the
instant induction of protective virus-specific immune responses by
a single immunization without the need for a booster vaccination
would be ideal. In the present study, we showed that a single
immunization with MVA-HA-VN/04 protected mice from severe
disease caused by infection with the homologous strain or the A/
Indonesia/5/05 strain, especially when a high dose (108 pfu) was
used. However, also vaccination with lower doses in the range of
105–106 pfu afforded clinical protection, in particular against the
homologous strain. In contrast to two immunizations, it was not
possible to induce sterilizing immunity after a single immunization
with MVA-HA-VN/04.
Collectively, we conclude that in addition to well-established
favorable properties of MVA based vaccines such as superior
safety, its good stability allowing stock-piling, high expression of
genes of interest and good immunogenicity without the use of
adjuvants, they also allow dose sparing. Two immunizations with
relatively low doses of MVA-HA-VN/04 induced protective
immunity against H5N1 viruses derived from different antigeni-
cally distinct clades. This vaccination strategy would be attractive
for prepandemic vaccination, when there is still enough time for
prime-boost regimens. Since there could be uncertainty about the
strain that ultimately would cause a pandemic, the possibility to
induce cross-clade immunity may afford broad protective
immunity against a variety of different strains. When the induction
of protective immunity becomes more urgent, a single immuni-
zation with a high dose might afford rapid protection against
infection with the emerging pandemic strain. Of course the
minimal requirements for the induction of protective immunity by
MVA-HA-VN/04 vaccination need to be confirmed in humans.
However, the potential of recombinant MVA-H5 vaccine was
confirmed in non-human primates [24] and therefore we
anticipate that also in humans dose sparing and single shot
regimens are feasible. In this respect the presence of anti-vector
immunity is considered to be a potential draw back of MVA based
vaccines. Indeed it was demonstrated that pre-existing immunity
to the vector especially affected T cell responses. This limitation
could be overcome by mucosal administration of the vaccine or by
using prime-boost regimens [34,35]. However, since MVA is fully
replication deficient, pre-existing immunity is unlikely to affect the
immunogenicity of these vector vaccines to a great extent and did
not prevent the induction of humoral responses to the expressed
protein [35–37]. Thus recombinant MVA is promising as a H5N1
vaccine candidate, but of course this technology can be applied to
other subtypes of influenza viruses as well. For example, it would
be of interest to evaluate its potential as candidate vaccine against
the pandemic influenza A/H1N1 virus that spread worldwide
within two months, causing more than 52,000 reported cases,
including over 231 deaths as of June 22nd 2009 [2].
Materials and Methods
Ethics Statement
The experimental protocol was approved by Stichting Dier
Experimenten Commissie (DEC) Consult before the start of the
experiments, which were conducted according to national and
international guidelines.
Vaccine Preparation
Recombinant MVA expressing the HA gene of influenza virus
A/Vietnam/1194/04 (MVA-HA-VN/04) was prepared as de-
scribed previously [25]. MVA clonal isolate F6 served as the
parental MVA virus. To generate final vaccine preparations, the
virus was amplified in chicken embryo fibroblasts (CEF), purified
by ultracentrifugation through sucrose, reconstituted in 1 mM
Tris-HCL pH 9.0 and diluted in PBS.
Viruses
Influenza viruses A/Vietnam/1194/04 (A/VN/1194/04) and
A/Indonesia/5/05 (A/IND/5/05) were cultured in Madin Darby
Canine Kidney (MDCK) cells. Infectious virus titers were
determined in MDCK cells as described previously [38].
Animals
Female specified pathogen free 6–8 weeks old C57BL/6J mice
were purchased from Charles River (Sulzfeld, Germany) and were
age-matched at the time point of the first immunization. Mice
were immunized once with MVA-HA-VN/04 at a dose of 103,
104, 105, 106, or 108 pfu in a volume of 100 ml intramuscularly in
the hind legs (20 mice per dose). A second group of animals was
immunized twice with MVA-HA-VN/04 at a dose of 103, 104,
105, or 106 pfu (20 mice per dose) with a time interval of four
weeks. For the control groups mice were immunized with wildtype
MVA (wtMVA) (106 (two shot) or 108 pfu (single shot)) (n = 60) or
PBS (n= 56). Four weeks after the last immunization blood was
drawn from the animals and they were infected with 103 TCID50
of the homologous influenza virus A/VN/1194/04 or 103 TCID50
of the heterologous influenza virus A/IND/05/05. Virus was
inoculated intranasally in a volume of 50 ml and the challenge dose
was chosen since it resulted in a lethal infection in .90% mice
reproducibly (data not shown). Four and fourteen days after
Minimal Dose MVA H5N1 Vaccine
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challenge infection mice were euthanized and their lungs were
resected. Blood sampling, the intranasal infection, and euthanasia
were carried out under anesthesia with inhalative isoflurane. The
animals were housed in individual ventilated cage units (IVC-
units) and had access to food and water ad libitum. During the
infection with the influenza A/H5N1 viruses, animals were housed
in type 3 cages placed in bio-safety level 3 containment facilities.
Serology
After treatment with cholera filtrate and heat-inactivation at
56uC, the sera were tested for the presence of anti-HA antibodies.
For this purpose a hemagglutination inhibition (HI) assay was used
following a standard protocol using 1% turkey erythrocytes and
four HA-units of influenza virus A/VN/1194/04 and A/IND/5/
05 [39]. For this purpose reverse genetics viruses were produced
from which the basic cleavage site in the HA molecule was deleted.
The antibody titers obtained with these viruses were comparable
with those obtained with the wild type strains (data not shown).
Sera were also tested for the presence of virus neutralizing
antibodies specific for the two influenza viruses using a micro virus
neutralization (VN) assay with the viruses that were produced by
reverse genetics as described above [40]. In brief, 50 ml volumes of
serial diluted serum samples were incubated with 100 TCID50 of
the viruses for one hour at 37uC and then the mixture was added
to MDCK cells. After one hour, the cells were washed and
subsequently cultured in Eagles Minimal Essential Medium
containing bovine serum albumin (BSA, fraction V 0.3%), 4 mg/
ml trypsin, L-glutamin 2 mM, penicillin 100 U/ml, streptomycin
100 mg/ml NaHCO3 0.15%, Hepes 20 mM and non-essential
amino acids 0.1 mM. After five days, residual virus replication was
assessed by measuring HA activity in the culture supernatants.
Hyper-immune serum obtained from a swan immunized twice
with inactivated H5N2 influenza virus A/Duck/Potsdam/1402/
86 (Nobilis influenzaH H5N2 Intervet International, Boxmeer, the
Netherlands) was used as a positive control against the two
influenza viruses. For calculation purposes serum samples with an
antibody titer of ,10 were arbitrarily assigned a titer of 5.
Lung Virus Titers
Lungs were snap frozen on dry ice with ethanol and stored at
270uC. Subsequently they were homogenized with a FastPrep-
24H (MP Biomedicals, Eindhoven, The Netherlands) in transport
medium (Hanks medium (MEM), lactalbumin, glycerol, penicillin,
streptomycin, polymyxin B, nystatin, gentamicin) and centrifuged
briefly. Quintuplicate ten-fold serial dilution of these samples were
used to determine the virus titers on confluent layers of MDCK
cells as described previously [38].
Histopathology and Immunohistochemistry
Formalin-inflated lungs (two mice per group) were fixed in 10%
neutral buffered formalin and then cross-sections were made and
embedded in paraffin, sectioned at 4 mm and stained with
hematoxylin and eosin for histological evaluation. Sequential
slides were stained using an immunoperoxidase method with a
monoclonal antibody (Clone HB65 IgG2a (American Type
Culture Collection)) directed against the nucleoprotein of influenza
A virus. a Goat-anti-mouse IgG2a HRP (Southern Biotech,
Birmingham, Alabama, USA) was used as secondary antibody.
The peroxidase was revealed using diamino-benzidine as a
substrate, resulting in a deep red precipitate in the nuclei of
influenza A virus-infected cells and a less intense red-staining of
their cytoplasm. The sections were counterstained with hematox-
ylin.
Statistical Analysis
Data for weight loss and viral titers were analyzed using the two-
sided Student’s t test and differences were considered significant at
P,0.05.
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